000299546 001__ 299546
000299546 005__ 20250530151900.0
000299546 0247_ $$2doi$$a10.1016/j.jvir.2025.02.028
000299546 0247_ $$2pmid$$apmid:40043833
000299546 0247_ $$2ISSN$$a1051-0443
000299546 0247_ $$2ISSN$$a1535-7732
000299546 037__ $$aDKFZ-2025-00490
000299546 041__ $$aEnglish
000299546 082__ $$a610
000299546 1001_ $$aTefera, Jonathan$$b0
000299546 245__ $$aPortal and Hepatic Vein Embolization vs Portal Venous Embolization Alone in Cirrhotic and Non-cirrhotic Swine: A Pilot Study.
000299546 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2025
000299546 3367_ $$2DRIVER$$aarticle
000299546 3367_ $$2DataCite$$aOutput Types/Journal article
000299546 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748610888_4403
000299546 3367_ $$2BibTeX$$aARTICLE
000299546 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000299546 3367_ $$00$$2EndNote$$aJournal Article
000299546 500__ $$aVolume 36, Issue 6, June 2025, Pages 1042-1050.e2
000299546 520__ $$aTo evaluate the effectiveness of PVE and HVE compared to PVE in cirrhotic and non-cirrhotic swine.Sixteen Yorkshire pigs were included in this study. In the cirrhotic group (n = 8) and non-cirrhotic group (n = 8), subjects underwent embolization according to established protocols. CT scans were acquired before and at two- and four-week intervals following the embolization. Liver volumes were segmented in the portal venous phase. Student's t-test with a significance level at p<0.05 was used.Across all swine, the FLR was significantly larger after PVE + HVE to PVE at two weeks (24.12% [95% CI: 15.36%, 32.88%] vs. 12.75% [95% CI: 7.43%, 18.07%], p = 0.021) and four weeks (23.23% [95% CI: 15.79%, 33.47%] vs. 15.08% [95% CI: 9.98%, 20.87%], p = 0.043) post-embolization. In the cirrhotic group, the FLR increase was greater following PVE + HVE compared to PVE at two weeks (20.85% [95% CI: 14.40%, 27.30%] vs. 8.66% [95% CI: 6.47%, 10.86%], p = 0.0089) and four weeks (19.27% [95% CI: 17.87%, 20.67%] vs. 13.33% [95% CI: 9.23%, 13.33%], p = 0.0003) post-embolization.PVE + HVE resulted in greater FLR hypertrophy than PVE alone indicating that cirrhotic livers may benefit from the addition of HVE.
000299546 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000299546 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000299546 7001_ $$0P:(DE-He78)19efdf048b5b493cad9ee8d86d3ae6bf$$aKuhn, Tom N$$b1$$udkfz
000299546 7001_ $$aMatuschewski, Nickolai J$$b2
000299546 7001_ $$aMeister, Ellen$$b3
000299546 7001_ $$aNguyenová, Jana$$b4
000299546 7001_ $$aKao, Tabea$$b5
000299546 7001_ $$aMutonga, Martin$$b6
000299546 7001_ $$aBitar, Ryan$$b7
000299546 7001_ $$aKahl, Vinzent$$b8
000299546 7001_ $$aZhang, Xuchen$$b9
000299546 7001_ $$aShewarega, Annabella$$b10
000299546 7001_ $$aChapiro, Julius$$b11
000299546 7001_ $$aMadoff, David C$$b12
000299546 773__ $$0PERI:(DE-600)2041331-2$$a10.1016/j.jvir.2025.02.028$$gp. S1051044325002209$$n6$$p1042-1050.e2$$tJournal of vascular and interventional radiology$$v36$$x1051-0443$$y2025
000299546 909CO $$ooai:inrepo02.dkfz.de:299546$$pVDB
000299546 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19efdf048b5b493cad9ee8d86d3ae6bf$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000299546 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000299546 9141_ $$y2025
000299546 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-01$$wger
000299546 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ VASC INTERV RADIOL : 2022$$d2025-01-01
000299546 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
000299546 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
000299546 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
000299546 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-01
000299546 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-01
000299546 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-01
000299546 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
000299546 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-01
000299546 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x0
000299546 980__ $$ajournal
000299546 980__ $$aVDB
000299546 980__ $$aI:(DE-He78)D170-20160331
000299546 980__ $$aUNRESTRICTED